Drug Labeling Volatility Index →

A pharmaceutical regulatory-intelligence agent monitors ADW-357 monthly and triggers a review-queue expansion whenever the score crosses above 60 (indicating drug-label activity running meaningfully hotter than the prior 12-month baseline). On that trigger, the agent calls the Signal tier to retrieve source_lineage — including the specific openFDA effective_time facet window — and spins up a downstream document-parsing workflow that pulls and classifies the incremental label changes by drug class and label section, enabling autonomous tracking of which therapeutic areas are driving the surge rather than requiring an analyst to manually triage FDA label RSS feeds.

A medical-affairs director at a mid-size pharma company uses ADW-357 monthly to calibrate how aggressively to staff their regulatory-affairs team. At the current reading of 54.0, labeling activity is running slightly above the neutral-50 baseline, which is directionally useful — but the real value comes when the score moves above 60 or below 40, signaling a materially accelerating or decelerating FDA labeling environment that would affect competitor label update velocity, their own label-maintenance workload, and the timing of supplemental NDA filings, all of which today require a manual count of FDA label publications that takes their team two days per month.